Strategikon Pharma, Inc. filed a Form D with the Securities and Exchange Commission on 2025-11-21.
Strategikon Pharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 21, 2025. The filing reports $2.29M sold. Its industry group is Other Technology. It names Anca Copaescu (Executive Officer, Director), Mark Weinstein (Executive Officer, Director), Nathanael Lentz (Director) (SEC Form D, November 21, 2025).
Is this your company?
Sell to companies like Strategikon Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Strategikon Pharma, Inc.
Free to see. No signup.
More on the people and the money behind Strategikon Pharma, Inc., from the filings we hold.
Other Technology raises by companies based in California, filed in November 2025, largest first.
Get an email when Strategikon Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Strategikon Pharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch Strategikon Pharma, Inc. →Get the full cited report on Strategikon Pharma, Inc.
What the filing shows about Strategikon Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Strategikon Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Strategikon Pharma, Inc.'s address as 1 Sansome Street, 35th Floor Pmb #40621, San Francisco, CA 94104.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Strategikon Pharma, Inc. See pricing
Strategikon Pharma, Inc. is a registered filer with the SEC (CIK 1722200) and has filed since 2025-11-21. 1 filing is on record, the latest on 2025-11-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Strategikon Pharma, Inc.'s Form D of 2025-11-21 names Anca Copaescu, Mark Weinstein, Nathanael Lentz and 5 more as its officers, directors or promoters.
Its new offerings report $2.29M sold across 1 offering, as its own filings state.
Trailing twelve months. 3844 filings in Other Technology, totalled by week. The dot is this raise, $2.29M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Anca Copaescu is named as Executive Officer and Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Mark Weinstein is named as Executive Officer and Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Nathanael Lentz is named as Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Rob Hess is named as Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Vincent Lepreux is named as Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Debra Apruzzese is named as Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Chris Codeanne is named as Director on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
Paulo Carvalho is named as Executive Officer on the Form D that Strategikon Pharma, Inc. filed with the SEC on 21 November 2025, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2025-11-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Strategikon Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Strategikon Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Strategikon Pharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Strategikon Pharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Strategikon Pharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Strategikon Pharma, Inc.. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/strategikon-pharma-inc-form-d-25000001